Martin, a veteran for 30 years, is currently the CEO and co-founder of Rallybio, formed to develop transformative therapies for patients with devastating ultra-rare diseases. He was Head of R&D at Alexion, where launches included Strensiq and Kanuma, in addition to a new indication for Soliris. At Pfizer, he led the R&D organization as the company prepared to launch Xeljanz, Xalkori and Eliquis; and other launches included Selzentry, Chantix, Sutent and Lyrica.